BAM
AVIR icon

Berkshire Asset Management’s Atea Pharmaceuticals AVIR Stock Holding History

Berkshire Asset Management’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-65,000
Closed -$215K – 282
2024
Q3 		$215K Hold
65,000
– – 0.01% 269
2024
Q2 		$215K Buy
+65,000
New +$242K 0.01% 271

Other funds holding AVIR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Berkshire Asset Management's AVIR Position: Q4 2024 in Review

Berkshire Asset Management sold out of Atea Pharmaceuticals (AVIR) in Q4 2024, closing a stake of 65,000 shares — an estimated $215K sold.

Berkshire Asset Management first reported a position in AVIR in Q2 2024 and held it in 2 quarters. The position peaked at $215K in Q3 2024. 106 funds tracked by Wall St. Rank hold AVIR as of Q4 2024.

  • Berkshire Asset Management reported no remaining Atea Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Berkshire Asset Management sold 65,000 Atea Pharmaceuticals shares in Q4 2024, an estimated $215K.
  • Berkshire Asset Management first reported a position in Atea Pharmaceuticals in Q2 2024 and held it in 2 quarters.
  • Berkshire Asset Management's Atea Pharmaceuticals position peaked at $215K in Q3 2024.
  • 106 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q4 2024.

Based on Berkshire Asset Management's 13F filing for Q4 2024, filed 7 Feb 2025.